



YALE PROGRAM IN
**ADDICTION
MEDICINE**

Year-in- Review

2025-26

The Yale Program in Addiction Medicine (YPAM) works to expand access to high-quality prevention, assessment, treatment, and harm reduction services for substance use, substance use disorders, and concomitant conditions.

Our faculty and affiliates provide evidence-based clinical care, conduct rigorous and innovative research, train the next generation of addiction specialists, and engage in policy and advocacy initiatives. We model, and work to advance, patient-centered non-stigmatizing care as the norm, and partner with government, community-based organizations, people who use substances, and their loved ones, to improve the health and wellbeing of all those impacted by addiction.

YPAM is affiliated with several departments, clinics, and initiatives spanning Yale School of Medicine (YSM), Public Health (YSPH), Nursing (YSN), and Law (YLS), Yale New Haven Hospital (YNHH), Yale New Haven Health, and community programs including the APT Foundation and Cornell Scott-Hill Health Center.

Year-in-Review 2025–26 is published by the Yale Program in Addiction Medicine.

Special thanks to:

Emma Biegacki, MPH
Rebecca Minahan-Rowley, LMSW
Chelsey Gutierrez, MS
Julie Parry, MS
Serena Crawford, MFA
Amy Anderson
DIM Communications
DIM Development

Correspondence about this report may be sent electronically to:

Rebecca Minahan-Rowley, LMSW
Project Manager
Yale Program in Addiction Medicine
rebecca.minahan-rowley@yale.edu



addictionmedicine.yale.edu



[@YaleADM](https://twitter.com/YaleADM)



[@yaleadm.bsky.social](https://bsky.app/profile/yaleadm.bsky.social)



[@yaleaddictionmed](https://www.instagram.com/yaleaddictionmed)



[Yale Program in Addiction Medicine](https://www.linkedin.com/company/yale-program-in-addiction-medicine)



Contents

Message from Our Director	3
Program Pillars	4
Clinical Practice	5
Setting the Standard for Pediatric Addiction Care	6
Mobile Pharmacy and Clinic Is Redefining Community Care	7
Clinical Tools & Resources	8
Education	9
2025–26 Addiction Medicine Fellowship Graduates	10
The RISE of Longitudinal, Integrated Addiction Medicine Education at Yale	11
Yale Launches New Street Medicine Training Program for Residents	12
2025–26 Addiction Medicine Grand Rounds	13
Research	14
At a Glance	15
Bridging Gaps in Integrated Care for Opioid Use Disorder and Chronic Pain	16
Integrating Tobacco Treatment in HIV Care	17
High-Potency Synthetic Opioids Are Changing How Doctors Treat Opioid Use Disorder in the Hospital	18
2025–26 Conference Highlights	19
Policy	20
Introducing the National Methadone Access and Quality Commission (NMAQC)	21
2025–26 Policy Publication Spotlight	22
Awards & Recognition	23
New Positions, Appointments & Promotions	24
In the Media	25
Faculty & Staff	27
Support Our Work	31

Message from Our Director

Welcome to the Yale Program in Addiction Medicine's (YPAM) second annual Year-in-Review report! I encourage you to take time and review the accomplishments of our faculty, fellows, residents, and students. They reflect the broad impact we are making in the areas of clinical practice, education, research, policy, and advocacy. You will be amazed at the depth and breadth of their work, across multiple sections, departments, and schools at Yale and the dedication YPAM affiliates have in caring for people who use substances and those with addiction.

Yale has been at the forefront of expanding treatment for substance use and addiction into general medical settings for over 30 years. This includes adult and pediatric primary care, emergency departments, HIV clinics, liver clinics, cancer centers, and hospitals. Our faculty and trainees are conducting cutting-edge research, providing timely, high-quality, and easily accessible care, and cultivating an environment of continuous learning and innovation that attracts and develops national and international leaders.

This year we highlight several clinical, educational, research, and policy milestones. These include greater access to contingency management for stimulant use disorder in primary care; extended-release medication for opioid use disorder in the emergency department, hospital, and outpatient settings; expanded mobile and street medicine initiatives; a faculty member, Melissa Weimer, DO, MCR, who literally “wrote the book” on hospital-based addiction medicine; novel and integrated training for physicians and advanced practice providers in addiction medicine; youth-focused clinical and research initiatives; and expanded national policy-setting programs.

Our motto, “No wrong door,” means that our breadth cuts across traditional medical disciplines and schools so that wherever a person presents to the medical system, someone is prepared to help them achieve their goals of care. We comprise specialists in addiction medicine and internal medicine, infectious disease, liver disease, pulmonary and critical care medicine, emergency medicine, pediatric and adolescent medicine, anesthesiology, hospital medicine, family medicine, and primary care. We also work closely with our colleagues in the Schools of Public Health, Nursing, Management, and Law to address many interdisciplinary issues.

It is with great pride that I encourage you to read this year's Year-in-Review. Please feel free to contact me with any thoughts or feedback you have.



David A. Fiellin, MD, DFASAM


Professor of Medicine and Emergency Medicine, Yale School of Medicine
Professor of Health Policy and Management, Yale School of Public Health
Vice Chief, Faculty Affairs, Section of General Internal Medicine
Director, Yale Program in Addiction Medicine



“Our faculty and trainees are conducting cutting-edge research, providing timely, high-quality, and easily accessible care, and cultivating an environment of continuous learning and innovation that attracts and develops national and international leaders.”


Program Pillars

The Yale Program in Addiction Medicine (YPAM) operates across four pillars—clinical practice, education, research, and policy.




Clinical Practice

Evidence-based clinical care delivered in outpatient, inpatient, community-based, and general medical settings.




Education

Training and education in evidence-based addiction care spanning medicine, nursing, public health, and allied health professions.



Research

Rigorous and innovative scientific inquiry to advance prevention, treatment, and harm reduction strategies, for substance use, addiction, and related conditions.



Policy

Advising and advocacy at the local, state, and national levels to facilitate legislation, regulation, clinical guidelines, and best practices that enhance access to equitable, quality care for the communities we serve.

Clinical Practice

For people with substance use disorder, every point of care can be an opportunity for connection to treatment and support services, guided by the principle of “no wrong door.” No matter where a patient enters the healthcare system, they should have the chance to receive high-quality care and referrals for substance use and addiction. The Yale Program in Addiction Medicine (YPAM) offers a robust spectrum of clinical services in community-based outpatient clinics, affiliated hospitals, and specialty care practices. Advancing the integration of substance use treatment into general medical settings and supporting adaptive models of care, including mobile and street-based medicine, are cornerstones of YPAM’s clinical practice mission.

Clinical programs affiliated with YPAM offer a range of services for substance use and substance use disorders, supported by a diverse faculty and multidisciplinary health professions trainees. Core clinical services include:

- The inpatient Yale Addiction Medicine Consult Service (YAMCS), which serves the York Street and Saint Raphael campuses of Yale New Haven Hospital (YNHH)
- Outpatient clinics at the APT Foundation as well as the Addiction Recovery Clinic (ARC) embedded within Cornell Scott-Hill Health Center
- A nationally renowned emergency department-initiated buprenorphine program
- A school- and hospital-based pediatric and adolescent consult service
- Specialty clinics serving individuals navigating reentry after a period of incarceration, those with medical comorbidities (e.g., HIV, hepatitis C, chronic pain, liver disease), and those with co-occurring psychiatric conditions.

Updates to clinical programs in 2025–26 include:

- Re-establishment of the ARC’s contingency management (CM) program for the treatment of stimulant use disorders.
- A new addiction medicine clinic through Yale Internal Medicine Associates (YIMA) recently marked its one-year anniversary. Under the leadership of Erica Heiman, MD, MS, assistant professor of medicine (general internal medicine) at Yale School of Medicine, YIMA integrates addiction medicine services into primary care.
- After two years of service, the InMOTION mobile pharmacy and clinic continues to drive community access to quality substance use and addiction treatment, with the National Institutes of Health recently awarding additional funds to expand integrated HIV care.
- In May 2026, Melissa Weimer, DO, MCR, and co-authors published *The Hospital Addiction Medicine Handbook*, a first-of-its-kind framework for hospital-based substance use disorder (SUD) screening, evaluation, and treatment based on the Yale model.

The ARC’s contingency management (CM) program is one of only a few in the region and provides patients with access to one of the effective interventions for stimulant use disorder with a robust evidence base. Implementation of CM at the ARC additionally affords our trainees the opportunity for dedicated didactics and hands-on clinical experience in CM.

Sami Hamdan, MD, MPH, ARC Contingency Management Program Director, Assistant Professor of Medicine (General Internal Medicine) Yale School of Medicine



Members of the Addiction Recovery Clinic’s Contingency Management Program, recently reestablished under the leadership of Stephen Holt, MD, MS, Sami Hamdan, MD, MPH, and colleagues.

Setting the Standard for Pediatric Addiction Care

adapted from an article originally published in YSM News

 [Click here for more.](#)

In January 2026, the Pediatric and Adolescent Addiction Consult Service at Yale New Haven Children's Hospital celebrated its five-year anniversary. Deepa Camenga, MD, MHS, associate professor of emergency medicine, pediatrics, and public health at Yale Schools of Medicine and Public Health, established the service in 2021 with collaboration from YPAM's adult Yale Addiction Medicine Consult Service (YAMCS). The service sees patients up to age 21 for at-risk substance use, mild to severe substance use disorders (SUDs), and associated complications such as overdose and withdrawal.

"It was apparent when we started that a great need was there in terms of treatment access and clinical competency," shares Camenga. "Children, teens, and families deserve hospitals and emergency departments prepared to provide evidence-based prevention and treatment interventions." Five years on, the impact extends well beyond the walls of the hospital. Camenga also says, "Not only has our presence at the Children's hospital influenced culture change at Yale, the service has emerged as a national model. Our team is regularly contacted by other clinicians near and far, looking to consult our expertise or establish something like this at their own institutions. We've provided proof of concept that this work is needed and has value." Indeed, Yale's model is one of the only such consult services in the country, and Yale New Haven Children's Hospital is the only hospital in the state of Connecticut offering withdrawal management for children.

Camenga notes increased awareness of substance use and addiction in pediatric and adolescent patient populations among hospital clinicians since launching the consult service. "They may not know exactly how to approach SUD in their pediatric patient, but they are willing to because they have a team they can call for consultation and support." The consult service has been instrumental in instituting training requirements for all pediatric nurses addressing substance use and addiction topics, and expanding access to hands-on clinical experience in pediatric and adolescent addiction medicine for Yale pediatric and child psychiatry fellows.

"Rotating on the pediatric and adolescent addiction consult service has immensely enriched the training afforded our addiction medicine fellows, providing them the opportunity to gain



experience treating substance use across the lifespan, engage with families and unique considerations in the care of minors, and contribute to cutting-edge practice," shared YAMCS Medical Director Melissa Weimer, DO, MCR, associate professor of medicine (general internal medicine) and of chronic disease epidemiology at Yale Schools of Medicine and Public Health.



Deepa Camenga, MD, MHS
Associate Professor of Emergency Medicine, Pediatrics, and Public Health

"As we look to the future, we're focused on sustainability and expansion to bring our expertise to other health systems, regionally and nationally. As many children's services are funded through Medicaid, federal policy is a key factor in our growth. We hope to continue building upon the foundation we've laid for excellent pediatric and adolescent care."

Mobile Pharmacy and Clinic Is Redefining Community Care



Click here for more.

adapted from an article originally published in YSM News



Can you highlight how this holistic model has broken down complex barriers to care for patients?

“InMOTION’s holistic model brings integrated medical, behavioral health, and social services directly to people, eliminating barriers that prevent engagement in traditional healthcare settings. By breaking down logistical, emotional, and financial barriers, InMOTION encourages people to engage and improve their health and well-being.”

What is the outlook for InMOTION’s long-term sustainability and growth?

“We plan to expand services to additional locations across Connecticut while supporting our current patients. We seek new partners to grow in-person and telehealth services. We hope more states and organizations recognize the value of these services in communities with the greatest need.”

Two years ago, Yale Medicine (YM) and Yale New Haven Health System (YNHHS) launched the first mobile retail pharmacy and clinic in the nation to bring healthcare to people where they live. InMOTION aims to make better healthcare accessible to anyone disconnected from the healthcare system. Yale School of Medicine recently interviewed project director Sandra Springer, MD, professor of medicine (infectious diseases).

How has the project lived up to its foundational goal?

“The Mobile Pharmacy Clinic (MPC) has become a trusted resource across communities, offering whole-person, stigma-free care that integrates medical, behavioral health, pharmacy, and social support services. A key achievement has been demonstrating the power of a mobile, hub-and-spoke health care model that provides clinical care and same-day access to medications. One success story involves a patient with opioid use disorder who came to the MPC. A community health worker helped them access medication treatment. The patient began treatment, connected with a local provider, and continues to progress in recovery.”



Sandra Ann Springer, MD
Professor of Medicine & Associate
Clinical Professor of Nursing

“Leading InMOTION has emphasized why I went into medicine: to help people who have been stigmatized access health care. Developing this mobile health care system and working directly with people who need services has been a tremendous experience.”

Clinical Tools & Resources

click each icon to learn more

YPAM faculty, staff, and trainees regularly contribute to national clinical resources and guidance in addiction medicine for multidisciplinary audiences. Selected resources from the last year are listed below. These tools are free and publicly accessible.



Providers Clinical Support System (PCSS) Alcohol Use Conversations Tool

Funded by the Substance Abuse and Mental Health Services Administration (SAMHSA) with leadership from YPAM faculty members, Melissa Weimer, DO, MCR, Stephen Holt, MD, MS, and multi-institutional collaborators, Providers Clinical Support System-Medications for Alcohol Use Disorder (PCSS-MAUD) is a continuing education unit-accredited online resource for healthcare professionals offering education and training on alcohol use disorder. The Alcohol Use Conversations Tool supports multidisciplinary clinicians in practicing alcohol counseling skills.



Shatterproof, Inc. “Provider’s Pathway: Supporting Patients with SUD” Modular Curriculum for Healthcare Clinicians

Developed by Shatterproof, Inc. with funding from the Elevance Health Foundation and design and evaluation support from YPAM faculty and staff, *Provider’s Pathway* offers a web-based asynchronous, modular course targeting reduction of clinician-held stigma toward substance use and substance use disorder as well as improved clinical knowledge and confidence. Learners are eligible to earn up to eight continuing education units upon completion.




Journal of the American Medical Association (JAMA) Patient Page: Methamphetamine Use Disorder

This free, downloadable informational handout developed by Cara Borelli, DO, and colleagues, for patients and their families affected by methamphetamine use, covers topics including potential health effects of methamphetamine, behavioral and medication-based treatments for methamphetamine use disorder, and harm reduction strategies.



Primary Care Pearls Podcast: Diagnosing and Managing Alcohol Use Disorder

Primary Care Pearls (PCP), an educational podcast led by patient stories, launched in July 2022 with collaboration from faculty, residents, and students within Yale School of Medicine’s Department of Internal Medicine. A two-episode series features Stephen Holt, MD, MS, associate professor of medicine (general internal medicine), on the topic of clinical best practices for diagnosis and treatment of alcohol use disorder.



Lippincott Williams & Wilkins The Hospital Addiction Medicine Handbook

Offering a first-of-its-kind framework for hospital-based substance use disorder screening, evaluation, and treatment, this new reference resource from Melissa Weimer, DO, MCR, associate professor of medicine (general internal medicine), and Susan Calcaterra, MD, MPH, offers practical guidance to multi-specialty hospital-based clinicians and healthcare leaders to expand essential SUD care in the hospital setting.

Education

The Yale Program in Addiction Medicine (YPAM) is preparing the next generation of addiction-trained healthcare professionals by providing clinical and research training to medical, advanced practice nursing, and physician associate (PA) students, as well as medical residents and clinical fellows.

Core educational offerings of YPAM include:

- The Accreditation Council for Graduate Medical Education (ACGME)-accredited Yale Addiction Medicine Fellowship for physicians
- The Substance use Skills Training to Advance INtegrated care (SUSTAIN) fellowship and faculty development program for advanced practice providers (APPs) including physician associates and nurse practitioners
- The Collaborative Behavioral Health and Addiction Medicine in Primary Care (CHAMP) program for medical residents and physician associate students
- The Responsive Integration of Substance use Education (RISE) program for multidisciplinary health professions learners
- K12 career development opportunities for junior faculty
- Twice-monthly public Addiction Medicine Grand Rounds offering continuing medical education (CME) credits to multidisciplinary audiences

These and other addiction medicine education and training programs at Yale are supported with federal funds from the Health Resources and Services Administration (HRSA), Substance Abuse and Mental Health Services Administration (SAMHSA), and National Institute on Drug Abuse (NIDA), among other sources. Under the leadership of Jeanette Tetrault, MD, professor of medicine and of epidemiology (chronic diseases), the Yale Addiction Medicine Fellowship for physicians trains four fellows annually. Entering its fourth year, SUSTAIN, directed by Kenneth Morford, MD, associate professor of internal medicine, offers one of the first addiction medicine fellowships for APPs, including nurse practitioners and physician associates, in the country. The program trains one fellow annually and provides professional development activities for faculty in the Yale School of Nursing and Physician Associate Program.

“The mission of RISE is to bring multiple addiction medicine curricular components for medical students, graduate nursing students, and physician assistant students under a comprehensive longitudinal training framework to address addiction education and training gaps and ultimately strengthen the addiction-trained clinical workforce.”

Cara Borelli, DO, RISE Program Director
Assistant Professor of Medicine (General Internal Medicine), Yale School of Medicine



In November 2025, RISE leadership and student awardees gathered in Portland, Ore., for the annual Association for Multidisciplinary Education and Research in Substance use and Addiction (AMERSA) conference.

2025-26 Addiction Medicine Fellowship Graduates

Delores Bani, MD, MHA

Residency: Quinnipiac University School of Medicine - St. Vincent Internal Medicine Program
Post-Fellowship Plans: Staff Physician, Connecticut Valley Hospital

**Maisy Crews, PA-C**

APP Program: Yale PA Program
Post-Fellowship Plans: APP, Yale Addiction Medicine Consult Service, Yale New Haven Health

**Natalie DeQuillfeldt, MD, MA**


Residency: University of Colorado Internal Medicine Program
Post-Fellowship Plans: General Internal Medicine/Addiction Medicine/Primary Care Physician at Northeast Medical Group (NEMG)

**John Fomeche, MD**

Residency: Stamford Hospital Internal Medicine Program
Post-Fellowship Plans: Primary Care/Addiction Medicine Physician, Northeast Medical Group (NEMG)

**Nicole Turturro, MD, MPH**

Residency: Montefiore Medical Center Internal Medicine Program
Post-Fellowship Plans: Assistant Professor, Internal Medicine, Albert Einstein College of Medicine



On June 4, 2026, fellows gathered (below) with family, friends, faculty, and staff for YPAM's annual fellowship graduation, hosted by Patrick O'Connor, MD, MPH, the Dan Adams and Amanda Adams Professor of General Internal Medicine. Remarks from YPAM leadership were followed by presentation of certificates, refreshments, and festivities.

Above (left to right): Jenna McDermit, FNP (2025 SUSTAIN Advanced Practice Provider Fellowship graduate), Delores Bani, John Fomeche, Natalie DeQuillfeldt, Nicole Turturro, Maisy Crews.



The RISE of Longitudinal, Integrated Addiction Medicine Education at Yale

Launched in 2023 with funding from the Substance Abuse and Mental Health Services Administration (SAMHSA), the Responsive Integration of Substance use Education (RISE) program facilitates a comprehensive longitudinal addiction training curriculum for medical, physician associate, and graduate nursing students at Yale. Bridging several didactic trainings and clinical rotation experiences offered by the Yale Schools of Medicine and Nursing, RISE has, to date, engaged over 700 health professions learners. RISE additionally funds learners who demonstrate a focused interest in substance use and addiction to attend relevant annual addiction conferences.

Through RISE-affiliated programming, learners have the opportunity to:

- Cultivate core competencies in substance use screening and evaluation
- Hone confidence in counseling on and providing pharmacologic and non-pharmacologic substance use disorder treatments
- Gain exposure to addiction medicine practice in outpatient and hospital-based clinical settings
- Develop knowledge and skills to reduce substance use associated risk and medical complications


Entering its third year, RISE continues to garner positive feedback from learners, who appreciate the interdisciplinary nature of RISE-affiliated trainings, diversity of clinical experiences, timeliness of curricular content, and practical guidance on engaging patients in conversations about their care.

RISE offers a gateway to higher-level training at Yale through such programs as YPAM's medical resident electives, addiction medicine training track for primary care residents, and clinical fellowships for advanced practice providers and physicians. Students completing RISE-affiliated clinical rotations have reported improved awareness of addiction medicine as a potential career option and increased interest in pursuing additional training in this area after completing their current degree program.

RISE Program Director Cara Borelli, DO, assistant professor of medicine (general internal medicine) shares, “even for learners going into other clinical specialties, we have received tremendous positive feedback on how RISE has changed how they treat patients with substance use disorders and how they plan to apply their learning in their careers.”

“Presenting at the annual American Society of Addiction Medicine conference through RISE was an incredibly rewarding experience! The opportunity to share ideas, collaborate with peers, and contribute to meaningful conversations in addiction medicine made the conference both professionally and personally impactful.”

Maryam Berih, Yale Medical Student, RISE Student Travel Award Recipient



In April, Yale medical student and RISE Student Travel Awardee Maryam Berih presented her research at the 2026 ASAM Annual Conference in Washington, D.C. Her project on opioide overdose care in emergency departments was conducted in collaboration with the Yale Department of Emergency Medicine.

Yale Launches New Street Medicine Training Program for Residents

adapted from an article originally published in YSM News  [Click here for more.](#)

More than 770,000 people in the United States go without stable housing on a given night. Yet many physicians receive limited training in how to manage the complex health and social needs of this population. Homelessness poses unique challenges, says Jeffrey Lin, MD, MPH, instructor of medicine (general internal medicine) at Yale School of Medicine (YSM). “When even basic needs like food, water, and shelter are missing, how do we expect patients to deal with chronic medical conditions, complex psychiatric histories, physical disability, or possible substance use?”

Building on existing street medicine and outreach efforts in New Haven, a new YSM training initiative will prepare future primary care physicians to deliver consistent, preventive care directly to patients on the street. The Yale Street Medicine Training Program, co-led by Lin and Benjamin Howell, MD, MPH, assistant professor of medicine (general internal medicine) at YSM, will be offered to residents in the Yale Internal Medicine Primary Care Residency Program.

Lin and Howell will partner with faculty across YSM as well as a range of university and community organizations, including the Cornell Scott-Hill Health Center’s Street Medicine team, Yale Street Psychiatry program, and the VA’s Homeless Patient Aligned Care Team clinic. They will also work closely with the Solomon Center for Health Law and Policy’s medical-legal clinic and community organizations such as the Downtown Evening Soup Kitchen, Community Health Care Van, and U-ACT.

Brad Richards, MD, MBA, associate professor of medicine (general internal medicine) and executive director of the Yale Internal Medicine Primary Care Residency Program says, “Our goal is that graduates of the Yale Street Medicine Training Program will go on to lead similar efforts in their own communities, strengthening the pipeline of physicians dedicated to advancing health equity.” “At the same time, we hope to create more consistent access to high-quality, compassionate primary care for our patients and



community partners—care that, over time, can build trust, reduce reliance on crisis services, and improve health outcomes in New Haven’s unhoused community.”



Benjamin Howell, MD, MPH
Assistant Professor of Medicine
(General Internal Medicine)

“The strength of this initiative lies in its collaborative foundation. Together, these partnerships ensure residents gain a holistic, inter-professional, and justice-oriented education, while patients benefit from care that is more coordinated, accessible, and responsive to their realities.”

2025–26 Addiction Medicine Grand Rounds

Yale Addiction Medicine Grand Rounds (AMGR) are free, continuing medical education (CME)-accredited lectures offered twice per month on a diverse array of topics related to substance use and addiction. Since transitioning to a fully virtual and public format in 2020, AMGR engagement has grown exponentially with attendees tuning in from across the country and, increasingly, around the world.

Speakers invited for the 2025–26 series represented over 11 disciplines in clinical medicine, public health, and the social sciences. Notable topics included neurodiversity and addiction, implementation of long-acting injectables, emerging adulterants in the unregulated drug supply, GLP-1s and alcohol use, medications for opioid use disorder and pregnancy, resilience and preparedness for addiction treatment systems, and federal and state policy.

In September 2025, Ayana Jordan, MD, PhD, the Barbara Wilson Professor of Psychiatry at the New York University Grossman School of Medicine, delivered her presentation, “Conducting Community-Engaged Research in the New Political Climate,” at the Ninth Annual Schottenfeld Lecture, in honor of Richard Schottenfeld, MD. Her presentation detailed strategies for equity-oriented, community-engaged research practices with historically marginalized populations.

2025–26 AMGR BY THE NUMBERS



23 grand rounds sessions held



49 states represented by attendees



43 countries represented by attendees



Faculty gather at a welcome dinner the evening before the Ninth Annual Schottenfeld Lecture with special guest Ayana Jordan, MD, PhD (fourth from left).



Scan to access free, on-demand lectures from the 2025–26 AMGR series and prior years.

Research

Yale Program in Addiction Medicine (YPAM) faculty conduct research funded by federal, institutional, and foundation grants. Research includes observational studies, randomized controlled trials, implementation science, policy analysis, and ethnographic research designed to discover, evaluate, implement, and disseminate effective strategies for substance use and addiction diagnosis, treatment, prevention, and harm reduction.

Faculty members contributed significantly to the scientific literature through the publication of original research, reviews, and scholarly commentary. Several faculty members also held positions of leadership on the editorial boards of prominent journals in addiction medicine and review committees for prestigious grants and awards. New research grants received this year from government, foundation, and institutional funders will support investigation across a range of topics, including but not limited to:

- Alcohol and Cannabis Misuse Among Assault-Injured Emerging Adults
- Smoking Cessation Medication and Rewards for Tobacco Use Disorder Among Persons with HIV
- Methadone Dose-Associated Risks and Outcomes in Opioid Use Disorder Treatment
- Optimizing HIV PrEP Decision Support for Adolescents and Young Adults with Unhealthy Substance Use

June 2026 marked the conclusion of a multi-year National Institutes of Health Helping to End Addiction Long-term (HEAL) award to establish the Integrative Management of Chronic Pain and Opioid Use Disorder for Whole Recovery-Yale Organizations United (IMPOWR-YOU) Research Center at Yale. The center focuses on addressing the overlap between opioid use disorder and chronic pain. In May, IMPOWR-YOU hosted the IMPOWR network's annual Research and Partnerships meeting in New Haven, Conn, comprising two days of presentations and reflection on the past five years' accomplishments.



IMPOWR researchers and partners convened in New Haven in May 2026 for the network's annual Research and Partnerships Meeting to discuss the network's legacy and future directions, share updates on core trials and pilot projects, and hear patient reflections on the collaborative research experience.

Highlighted Studies



Clinical Pharmacists, Medications, and Contingency Management for Targeting Smoking in HIV Clinics: An RCT

E. Jennifer Edelman et al.
JAMA Network Open

[Click to Read](#)



Emergency Department-Initiated Buprenorphine for Opioid Use Disorder: An RCT

Gail D'Onofrio et al.
JAMA

[Click to Read](#)



Best Practices for Hospital-Based Initiation of Medications for Opioid Use Disorder: A Consensus Statement

Shawn Cohen et al.
JAMA Network Open

[Click to Read](#)

"We think IMPOWR-YOU has lived up to the aims we set out to achieve regarding highly partner engaged clinical research in this critical yet understudied area, we are excited to disseminate results and move to the next phase of implementation."

Will Becker, MD

Professor of Medicine
Yale School of Medicine and VA
Connecticut Healthcare System

Research at a Glance

click each icon to learn more



Core faculty and colleagues published 112 papers during the 2025–26 academic year in such journals as *JAMA*, *JAMA Network Open*, *JAMA Internal Medicine*, *Annals of Internal Medicine*, *Lancet HIV*, *American Journal of Public Health*, *Pediatrics*, *Journal of General Internal Medicine*, *Annals of Emergency Medicine*, *British Medical Journal*, *Drug & Alcohol Dependence*, *Journal of Addiction Medicine*, *International Journal on Drug Policy*, and *Harm Reduction*, among others.

Core faculty lead four research centers alongside multi-institutional collaborators, including the Clinical Trials Network (CTN) Consortium Node, the Veterans Affairs Family of Research Cohorts (VACo), and the Integrative Management of Chronic Pain and Opioid Use Disorder for Whole Recovery-Yale Organizations United (IMPOWR-YOU) Research Center.



A growing collection of publicly accessible toolkits developed to disseminate practice-changing research is available on the YPAM website. Currently available toolkits support implementation of emergency department-initiated buprenorphine, substance use disorder treatment integration for primary care and HIV clinics, as well as stepped care and contingency management for alcohol use.

Program core and affiliated faculty, including long-established leaders in the field and early-career investigators, won 10 research awards during the 2025–26 academic year recognizing exceptional contributions to research and addiction science, bestowed by federal agencies, professional associations, nonprofit organizations, and other entities.



Bridging Gaps in Integrated Care for Opioid Use Disorder and Chronic Pain

adapted from an article originally published in YSM News  [Click here for more.](#)



In the United States, over half of individuals with opioid use disorder (OUD) are also living with chronic pain (CP). Yet, treatment of OUD and CP is largely separated within the American healthcare system and clinical research driving discovery and innovation similarly siloed. In 2021, researchers at Yale School of Medicine (YSM) set out to bridge that gap by establishing the IMPOWR-Yale Organizations United (YOU) Research Center. In the last five years, this National Institute on Drug Abuse (NIDA)-funded initiative has developed a robust model for engaging people with lived experience (PWLE) of OUD and CP in the research process, launched two clinical trials, and facilitated several innovative pilot studies exploring novel treatment solutions.

One such pilot study, led by Michele Buonora, MD, MS, assistant professor of medicine at Albert Einstein College of Medicine, and Christin Veasley, co-founder and director of the Chronic Pain Research Alliance and individual with lived experience of CP, examined patient perspectives on satisfaction with clinical care for CP among patients with prescribed and non-prescribed opioid use.

“Co-leading a study with [Christin] - and guided

by a diverse team of patients, veterans, insurers, clinicians, scientists, and advocates—was a transformative experience. This approach was essential in shaping our research question into a rigorous study with rich findings and implications relevant and useful to those most impacted by our work,” reflects Buonora.

The center additionally houses two core clinical trials exploring novel integrated treatment approaches for OUD and CP: Pain CHAMP (Collaborative Care for Patients Prescribed Long-Term Opioids) and SC-POWR (Stepped Care for Patients to Optimize Whole Recovery).

Five pilot studies have been funded to date, and trial data will be made available in early 2027. In May 2026, the center welcomed partners to New Haven for two days of programming to review achievements of the last five years and discuss future directions as the center’s initial funding period draws to a close.



Declan Barry, PhD
Professor of Psychiatry, Yale School of Medicine;
Co-Director, IMPOWR-YOU Research Center

“Engagement with communities is really baked into the structure of the center. PWLE have been involved at every step from proposal to award and implementation. This is an innovative, fantastic feature of the center.”

Integrating Tobacco Treatment in HIV Care



[Click here for more.](#)

adapted from an article originally published by Avi Patel in YSM News



integrating tobacco cessation into HIV care. Can you share more about the model you developed?

“Because not all cessation treatments work for everyone, we wanted to build an adaptive approach that allows us to readily tailor care to the patient, recognizing that behavior change is complex and patients need options and adjustments over time. Our study was designed with that adaptability in mind. We’ve brought physicians, advanced practice providers, clinical pharmacists, social workers, psychologists, nurses, medical assistants, and others together in a collaborative setting to offer a range of interventions, including counseling, medications, and behavioral strategies like contingency management.”



[Click to read this study.](#)

With today’s therapies, many people living with HIV can expect long, full lives. But as patients age, the biggest threats to their health are often the same ones facing the general population—heart disease, cancer, and chronic lung conditions. Smoking is a major contributor to those risks. In a recent interview, E. Jennifer Edelman, MD, MHS, professor of medicine (general internal medicine) at Yale School of Medicine, discussed her recent study testing adaptive, team-based strategies to integrate tobacco treatment into HIV clinics.

If smoking is so consequential, why is it still a lower priority in HIV clinics?

“Both patients and providers are often focused on other pressing issues—viral suppression, medication adherence, housing instability, and mental health concerns. Tobacco use can fall down the list. At the same time, the smoking cessation treatments we have aren’t perfect. They don’t work for everyone, and tobacco use disorder is a chronic, relapsing condition.”

Your study, A SMART Approach to Treating Tobacco Use Disorder in Persons With HIV (SMARTTT) evaluates new approaches to



E. Jennifer Edelman, MD, MHS
Professor of Medicine
(General Internal Medicine)

“Through this work, we are outfitting multidisciplinary clinicians with the tools they need to support smoking cessation among their patients with HIV and providing our patients with more choice and flexibility in their care.”

High-Potency Synthetic Opioids Are Changing How Opioid Use Disorder Is Treated in the Hospital

 [Click here for more.](#) adapted from an article originally published in YSM News



Fentanyl and other high-potency synthetic opioids (HPSOs) are the leading cause of opioid overdose deaths in the United States. These substances have changed the way that hospitals start medication to treat opioid use disorder (OUD), but no standards exist.


A new study published in JAMA Network Open in May 2026 engaged 42 national experts in hospital-based addiction treatment in a consensus-building process to develop best practices for hospital-initiated medications for opioid use disorder (MOUD).

“Fentanyl and other HPSOs are different from other opioids in the drug supply. They’re orders of magnitude more potent, which not only contributes to the overdose crisis and more severe withdrawal we’re seeing clinically, but they can complicate treatment because of the other properties they contain. Hospital-based addiction medicine clinicians have often led the way in adapting to changes in the drug supply and helping improve care for people with opioid use disorder,” explains Shawn Cohen, MD, assistant professor of medicine (general internal medicine) at Yale School of Medicine (YSM) and lead author of the study.

The study distilled expert consensus around the appropriateness of emerging rapid methadone initiation, high-dose, and low-dose buprenorphine initiation protocols, adjunctive strategies for managing opioid withdrawal, and integration of long-acting injectables. Broad consensus around many of these adaptations signals practice changes that are becoming standard of care as the unregulated opioid supply continues to evolve.

While clinicians continue to innovate at the bedside, researchers have an opportunity to strengthen the supporting science. In addition to further study of the safety and effectiveness of practice adaptations emerging in response to HPSOs, the authors call for clear communication and shared decision-making with patients.



 [Click to read this study.](#)



Shawn Cohen, MD
Assistant Professor of Medicine
(General Internal Medicine)

“We hope this consensus-backed guidance can help improve MOUD initiation in the hospital and highlight where more research is needed. We need to continue to find ways to adapt our care rapidly using the best evidence and knowledge we can.”

2025-26 Conference Highlights



Policy

The Yale Program in Addiction Medicine (YPAM) conducts policy research and advises institutional, local, state, and federal partners in order to advance access to evidence-based treatments and harm reduction strategies for substance use and substance use disorders, reduce substance use stigma and discrimination, and facilitate community awareness.

Efforts primarily focus on the effect that policies and laws have on:

- Cost and quality of addiction treatment
- Substance use and addiction-related health disparities
- Overdose prevention and response
- Multilevel regulation of prevention, treatment, and harm reduction
- Clinical guidelines
- Health professions workforce development
- Special populations such as individuals who are unhoused, involved in the criminal legal system, or living with other chronic medical or psychiatric conditions

In January 2026, the Yale Program in Addiction Medicine, in collaboration with the Foundation for Opioid Response Efforts (FORE), launched the National Methadone Access and Quality Commission (NMAQC), which, with an establishing three-year grant, will seek to advance evidence-based policies and practice, as well as consensus around key questions and opportunities, pertaining to methadone treatment for opioid use disorder in the United States.

Over the course of the academic year, program core and affiliated faculty published widely on policy and advocacy topics, including but not limited to policy and practice implications of Medicaid coverage and expansion; opportunities to improve provision of addiction treatment services in hospitals, emergency departments, mental health treatment facilities, prisons, and jails; cost-effectiveness of selected harm reduction interventions; and more. Selected publications are highlighted on page 22 of this report.

“The opioid crisis demands that we look honestly at what works and how to make effective treatment more accessible. [...] FORE is pleased to convene the National Methadone Access and Quality Commission, which will bring together diverse experts and voices with a shared goal of advancing high-quality, patient-centered, life-saving care.”

Karen Scott, MD, MPH, President,
Foundation for Opioid Response Efforts



Members of the NMAQC convened in New York in January 2026 for the NMAQC's first annual in-person meeting to discuss initial priorities and objectives of the commission.

Introducing the National Methadone Access and Quality Commission (NMAQC)



The Foundation for Opioid Response Efforts (FORE) has awarded a grant to Yale University to establish the National Methadone Access and Quality Commission (NMAQC), a new national initiative focused on improving access to methadone, an evidence-based treatment for people with opioid use disorder (OUD).

The commission, chaired by David Fiellin, MD, director of the Yale Program in Addiction Medicine and professor of medicine, emergency medicine, and public health at the Yale Schools of Medicine and Public Health, brings together leading experts from addiction medicine, public health, policy, and healthcare delivery, as well as individuals with lived experience of methadone treatment for OUD, to inform policy and clinical practice change and increase public understanding of methadone treatment.

Research suggests that currently only one in five individuals who could benefit from medication treatment for OUD receive it. One of those medications is methadone, a long-standing, evidence-based treatment that has been used for decades and is particularly effective in treating fentanyl-related addiction.

Despite the strong evidence base, access to methadone has been limited by stigma, the regulatory complexities of dispensing it, and differing perspectives on best practices for monitoring its use.

The commission will examine key issues related to methadone access and quality, including:

- Patient experiences of methadone treatment
- Regulatory and policy barriers that inhibit access
- Opportunities to enhance clinical practice standards and workforce development
- Impacts of financing and reimbursement models
- Innovations in treatment delivery models
- Public health impacts

 [Click to read the press release.](#)



David Fiellin, MD

Professor of Medicine (General Internal Medicine), Emergency Medicine, and Public Health

“By bringing together clinical, policy, and lived-experience perspectives, we aim to help expand access to methadone treatment, improve the patient experience, and reduce preventable overdose deaths.”

click each icon to
read the article


2025–26 Policy Publications Spotlight



Medicaid: Increased Patient Access To MOUD In Residential Treatment Associated With Facility Openings And Closures, 2012-22

Beetham T, Newton H, Ndumele CD, Fiellin DA, Busch S. Health Affairs. 2025 Sept; 44(9): 1122-1130

States' implementation of the Medicaid Section 1115 SUD-Institution for Mental Disease (IMD) waiver policy increased residential addiction treatment access and quality. Most of the improvement was explained by facility turnover. Future policy should consider this and associated incentive structures, especially in cases where there may be cultural resistance to change.



Treating Chronic HCV Infections in Jail Is Feasible and Cost-Effective—What Now?

Howell BA, Kennedy BS. JAMA Internal Medicine. 2026 Mar 26; 186 (5): 595-596

With the advent of the direct-acting antivirals to treat hepatitis C virus (HCV), there has been hope of eliminating chronic HCV infections. The U.S. Department of Health and Human Services laid out a National Hepatitis C Elimination Program. Included in that program is a focus on supporting HCV treatment in people held in prisons and jails.



Private Equity Acquisition and Buprenorphine Prescribing

Holdaway T, Busch SH, Reimer J, Beetham T, Fiellin DA, King M. JAMA Network Open. 2026 Mar 2; 9(2)

Private equity investment in U.S. healthcare, including substance use disorder treatment, has grown. Oversight and research are necessary to ensure incentives for private investment in addiction care align with delivery of high-quality evidence-based treatment.



Actions Needed for Pharmacy-Dispensed Methadone for Opioid Use Disorder in the United States

Weinstein ZM, Bratberg J, Joudrey PJ, Fiellin DA. Journal of General Internal Medicine. 2026 Mar; 41(4): 1138-1141

Practical steps for clinicians and policymakers to take to overcome barriers to implementation of pharmacy-dispensed methadone include ensuring insurance coverage for methadone, removing methadone from the algorithms that limit the amount of controlled substances pharmacies can order, and obtaining concentrated methadone formulations.

Awards & Recognition

Susan Busch, PhD, and colleagues

Team Science Award for “Medicaid: Increased Patient Access to MOUD in Residential Treatment Associated with Facility Openings and Closures, 2012–22.”
Yale School of Public Health

Deepa Camenga, MD, MHS

Blue Ridge Institute for Medical Research
2025 Top NIH-Funded Researcher
National Ranking, Emergency Medicine

Alyssa Cheng, DO

Ruth Fox Scholarship Recipient, American Society of Addiction Medicine (ASAM)

Edouard Coupet II, MD, MS

Blue Ridge Institute for Medical Research
2025 Top NIH-Funded Researcher
National Ranking, Emergency Medicine

Gail D’Onofrio, MD, MS

Blue Ridge Institute for Medical Research
2025 Top NIH-Funded Researcher
National Ranking, Emergency Medicine

David Fiellin, MD

2026 James L. Sorensen Distinguished Treatment and Service Research Mentorship Award, College on Problems of Drug Dependence (CPDD)

John Fomeche, MD

Ruth Fox Scholarship Recipient, American Society of Addiction Medicine (ASAM)

Kathryn Hawk, MD, MHS

Blue Ridge Institute for Medical Research
2025 Top NIH-Funded Researcher
National Ranking, Emergency Medicine

Rebekah Heckmann, MD, MPH, MPA

Blue Ridge Institute for Medical Research
2025 Top NIH-Funded Researcher
National Ranking, Emergency Medicine

Kaveh Khoshnood, PhD

2025 Hecht Global Health Faculty Network Award, *SHIELD-Sudan: Strengthening Health Intelligence in Conflict-Affected Areas*, Yale School of Public Health

Ryan McNeil, PhD

Clarivate 2025 Highly Cited Researchers List

Ted Melnick, MD, MHS

Blue Ridge Institute for Medical Research
2025 Top NIH-Funded Researcher National Ranking, Emergency Medicine

Marc Potenza, MD, PhD

Pedro Ruiz Academic Fellowship on Psychiatry and Dual Disorders, World Association on Dual Disorders and World Psychiatric Association

Clarivate 2025 Highly Cited Researchers List

Caitlin Ryus, MD, MPH

2026 Social Advocacy Award, Society of Academic Emergency Medicine

Kimberly Sue, MD, PhD, and colleagues

American Society of Addiction Medicine (ASAM) 2026 Abstract Submission Award - Best Overall

June-Marie Weiss, MEd

2026 Internal Medicine Service Excellence Award, Department of Internal Medicine, Yale School of Medicine

New Positions, Appointments & Promotions

Joshua Bia, MD

Promoted to Assistant Professor,
Emergency Medicine, Yale School of
Medicine

Cara Borelli, DO

Promoted to Assistant Professor of
Medicine (General Internal Medicine), Yale
School of Medicine

Jenna Butner, MD, MPH, FASAM, AAHIVS

Board of Directors, Association for
Multidisciplinary Education and Research in
Substance use and Addiction (AMERSA)

Alyssa Cheng, DO

Appointed Instructor, Internal Medicine,
Yale School of Medicine

David Fiellin, MD

Appointed Distinguished Fellow of the
American Society of Addiction Medicine
(ASAM)

John Fomeche, MD

Appointed 2025 Alcohol and Other Drugs
Health Rich Saitz Editorial Intern, American
College of Academic Addiction Medicine
(ACAAM)

Ariadna Forray, MD

Promoted to Professor, Psychiatry, Yale
School of Medicine

Gregg Gonsalves, PhD

Promoted to Professor, Epidemiology
(Microbial Diseases), Yale School of Public
Health

Thomas Hickey, MD, MS, FASA

Promoted to Associate Professor,
Anesthesiology, Yale School of Medicine

Jennifer Kapo, MD

Promoted to the Sherwin B. Nuland and
Michael K. Vlock Professor, Internal
Medicine, Yale School of Medicine

Robert Kerns, PhD

Appointed Board Chair, A Place to Nourish
Your Health (APNH)

Haidong Lu, PhD

Appointed Assistant Professor of Medicine
(General Internal Medicine), Yale School of
Medicine

Jaimie Meyer, MD, MS, FACP

Appointed Scientific Member, Department
of Health and Human Services Panel on
Antiretroviral Guidelines for Adults and
Adolescents, NIH Office of AIDS Research
Advisory Council

Kenneth Morford, MD, FASAM

Promoted to Associate Professor, Internal
Medicine, Yale School of Medicine

Srinivas Muvvala, MD, MPH

Appointed Medical Director, Connecticut
Mental Health Center

Ijeoma Opara, PhD, LMSW, MPH

Appointed Visiting Professor, New York
University Silver School of Social Work

Manuel Paris, PsyD

Promoted to Professor, Psychiatry, Yale
School of Medicine

Ismene Petrakis, MD

Appointed Editor in Chief, American Journal
on Addictions

Julia Shi, MD

Appointed Medical Director, APT
Foundation

Daniel Tobin, MD, FACP

Promoted to Professor, Internal Medicine,
Yale School of Medicine

Minhee Sung, MD

Promoted to Assistant Professor of
Medicine (General Internal Medicine), Yale
School of Medicine

In the Media

click each title to
read the article

LOCAL

Prediction Markets Spark Bigtime Debate in Connecticut as State Looks at New Laws
Connecticut Insider

SB395: Put Buprenorphine in Emergency Departments
Connecticut Mirror

This CT Recovery Coach Could Lose His Job to Federal Cuts. What Will Happen to His Clients?
Connecticut Mirror

Tips for Navigating Your First Christmas Sober
News 8 WTNH

What to Know About Alcohol Consumption Ahead of St. Patrick's Day
News 8 WTNH

NATIONAL

A Chilling Risk of Recreational Nitrous Oxide Use: Frostbite
Mother Jones

Alcohol Use Is Up Among Women - and Health Consequences Have Followed
NBC 4 New York

Are Republicans Turning Against Medications for Treating Opioid Addiction?
STAT News

Can Weed Help You Drink Less? Scientists Study How Well 'California Sober' Works
NPR

Caregiving in the Shadow of Addiction
AARP

Centralized Federal Gatekeeping Isn't the Only Way to Ensure Safety
The Washington Post

Few Mental Health Facilities Offer AUD Medications
Psychiatric News

Here's What Addiction Specialists Say About 'The White Lotus'
Bloomberg

How Much Alcohol Is Too Much
IM Matters - ACP

How TikTok Keeps Its Users Scrolling for Hours a Day
The Washington Post

How the Insurance System Quietly Undoes Recovery From Addiction
STAT News

How Video Games Are Shaping a Generation of Boys, for Better and Worse
The New York Times

Is Moderate Drinking Good or Bad for You?
Everyday Health

My Patient Received Dangerous AI Medical Advice. Here's the Simple Question I Wish All Doctors Would Ask
Huffington Post

Safer Opioid Supply, Methadone Effective Treatment Options
Medscape

The Long, Strange History of Nitrous Oxide, a Popular Drug Users Have Been Inhaling for Hundreds of Years
The Smithsonian

Treating Addiction
NIH Research in Context

What's Worse Than a Hangover? Hangxiety. Here's Why it Happens
National Geographic

NATIONAL continued

When Addiction Treatment Is Involuntary
The New York Times

Why Alcohol Use Disorder Is So Different in Women
Psychology Today

Why Is Harm Reduction on the Chopping Block?
The Fulcrum

Why Some Doctors Are Pushing to End Routine Drug Testing During Childbirth
Mother Jones

Women Are Drinking More—And Doctors Are Worried
The Wall Street Journal

INSTITUTIONAL

Dasgupta Wins Genius Grant for Creative and Effective Harm Reduction Work
Yale School of Public Health

Differences in Experiences Must Influence Interventions
Yale School of Medicine

For Young Adults, Improving Sleep Is an Incentive To Drink Less
YaleNews

Higher Drinking Frequency Corresponds to Lower Synaptic Density in People with Alcohol Use Disorder
Yale School of Medicine

How Overdose Prevention Centers Can Change the Game in the Fight Against the Opioid Epidemic
Yale Daily News

Improving Opioid Use Disorder Treatment After Emergency Department Visits
Yale School of Medicine

In the U.S., Rising Temperatures May Increase Overdose Deaths
Yale School of Medicine

Inpatient Psychiatry Treatment Programs Must Step Up To Integrate Opioid Use Disorder Treatment
Yale School of Medicine

Medicaid Reimbursement Boosts Access to Opioid Treatment at New Facilities
Yale School of Public Health

Medications for Alcohol Use Lacking in U.S. Mental Health Treatment Facilities
Yale School of Public Health

Methadone: Public Transit Is a Barrier for Accessing Treatment
Yale School of Medicine

New “HOPE” for HIV Prevention and Addiction in Prison
Yale School of Medicine

Opioid Overdose Crisis: Medications Prevent Subsequent Overdoses
Yale School of Medicine

Private Equity Ownership Tied to Lower Psychiatric Hospital Staffing, Higher Quality Performance
Wash U - The Source

Research Project Studies High Doses of an Opioid Use Disorder Medication Among Veterans
Yale School of Medicine

Seven-Day Injectable, Daily Tablet Buprenorphine Equally Effective for ED Patients with Opioid Use Disorder
YaleNews

Women’s Brains on Alcohol: Insight Into the Science on Sex-Based Risks
Yale School of Medicine

LISTEN IN: PODCASTS, INTERVIEWS & MORE

Gail D’Onofrio, MD, MS
Rethinking Addiction Care in Emergency Medicine
Stanford Emergency Medicine Podcast

Thomas Hickey, MD
Buprenorphine Versus Full Agonist Opioids for Acute Post-Operative Pain Management
RAPM Focus

Thomas Hickey, MD
Buprenorphine with Tom Hickey
AACRAC Podcast

Core Faculty



David Fiellin, MD
Professor of Medicine (General Internal Medicine) and Emergency Medicine, Yale School of Medicine; Professor of Health Policy and Management, Yale School of Public Health; Director, Yale Program in Addiction Medicine



Jeanette Tetrault, MD, FACP, FASAM
Professor of Medicine (General Internal Medicine), Yale School of Medicine, and of Epidemiology (Chronic Diseases), Yale School of Public Health; Associate Director of Education and Training, Yale Program in Addiction Medicine



Stephen Baldassarri, MD, MHS
Assistant Professor of Medicine (Pulmonary, Critical Care and Sleep Medicine), Yale School of Medicine



William Becker, MD
Professor of Medicine (General Internal Medicine), Yale School of Medicine



Joshua Reed Bia, MD
Assistant Professor of Emergency Medicine, Yale School of Medicine



Cara Borelli, DO
Assistant Professor of Medicine (General Internal Medicine), Yale School of Medicine



Jenna L. Butner, MD, MPH, FASAM, AAHIVS
Assistant Professor Adjunct of Medicine, Yale School of Medicine; Assistant Clinical Professor, Yale School of Nursing



Deepa Camenga, MD, MHS, FAAP
Associate Professor of Emergency Medicine, Yale School of Medicine; Associate Director of Pediatric Programs, Yale Program in Addiction Medicine



Alyssa Cheng, DO
Instructor (General Internal Medicine), Yale School of Medicine



Shawn Cohen, MD
Assistant Professor of Medicine (General Internal Medicine), Yale School of Medicine



Edouard Coupet II, MD, MS
Assistant Professor of Emergency Medicine, Yale School of Medicine



Gail D'Onofrio, MD, MS
Albert E. Kent Professor of Emergency Medicine, Yale School of Medicine; Professor of Epidemiology (Chronic Diseases), Yale School of Public Health



Joseph Donroe, MD, MPH
Associate Professor of Medicine (General Internal Medicine), Yale School of Medicine



E. Jennifer Edelman, MD, MHS, AAHIVS
Professor of Medicine (General Internal Medicine), Yale School of Medicine



Caroline Falker, MD
Assistant Professor of Medicine (General Internal Medicine), Yale School of Medicine



Sami Hamdan, MD, MPH
Assistant Professor of Medicine (General Internal Medicine), Yale School of Medicine



Lamia Y. K. Haque, MD, MPH
Assistant Professor of Medicine (Digestive Diseases); Director, Yale Clinic for Alcohol and Addiction Treatment in Hepatology, Digestive Diseases



Kathryn Hawk, MD, MHS
Associate Professor of Emergency Medicine, Yale School of Medicine; Associate Professor of Epidemiology (Chronic Diseases), Yale School of Public Health

Core Faculty Cont.



Rebekah Heckmann, MD, MPH, MPA

Assistant Professor of Emergency Medicine and Anesthesiology, Yale School of Medicine



Erica Heiman, MD, MS, FACP

Assistant Professor of Medicine (General Internal Medicine), Yale School of Medicine



Thomas Hickey, MD, MS, FASA

Associate Professor of Anesthesiology, Yale School of Medicine



Stephen Holt, MD, MS, FACP, FASAM

Associate Professor of Medicine (General Internal Medicine), Yale School of Medicine; Director, Addiction Recovery Clinic



Benjamin Howell, MD, MPH, MHS

Assistant Professor of Medicine (General Internal Medicine) Yale School of Medicine



Haidong Lu, PhD

Assistant Professor of Medicine (General Internal Medicine), Yale School of Medicine; Assistant Professor of Epidemiology (Chronic Diseases), Yale School of Public Health



Ryan McNeil, PhD

Associate Professor of Medicine (General Internal Medicine), Yale School of Medicine; Associate Director, Harm Reduction Research, Yale Program in Addiction Medicine



Jaimie Meyer, MD, MS, FACP

Associate Professor of Medicine (Infectious Diseases, AIDS), Yale School of Medicine; Associate Professor of Epidemiology (Chronic Diseases), Yale School of Public Health



Kenneth Morford, MD, FASAM

Associate Professor of Medicine (General Internal Medicine), Medical Director, Physician Associate Program, SUSTAIN Program Director, Yale School of Medicine



Patrick O'Connor, MD, MPH, MACP

Dan Adams and Amanda Adams Professor of General Internal Medicine, Yale School of Medicine



Lisa Puglisi, MD

Associate Professor of Medicine (General Internal Medicine), Yale School of Medicine



Caitlin Ryus, MD, MPH

Assistant Professor of Emergency Medicine, Yale School of Medicine



Sarita Soares, MD, FACP

Associate Professor of Medicine (General Internal Medicine), Yale School of Medicine



Sandra Ann Springer, MD

Professor of Medicine (Infectious Diseases), Yale School of Medicine; Associate Clinical Professor of Nursing, Yale School of Nursing



Kimberly Sue, MD, PhD

Assistant Professor Adjunct of Medicine (General Internal Medicine), Yale School of Medicine



Minhee Sung, MD

Assistant Professor of Medicine (General Internal Medicine), Yale School of Medicine



Melissa Weimer, DO, MCR, DFASAM

Associate Professor of Medicine (General Internal Medicine), Yale School of Medicine; Associate Professor of Epidemiology (Chronic Diseases), Yale School of Public Health; Medical Director, YAMCS

Affiliated Faculty

Adam Ackerman, MD, FACP, Hospital Medicine
Kammarauche Aneni, MBBS, MHS, Child Psychiatry
Lydia Aoun-Barakat, MD, Medicine (Infectious Diseases)
Bubu Banini, MD, PhD, Medicine (Digestive Diseases)
Declan Barry, PhD, Psychiatry
Chyrell Bellamy, MSW, PhD, Psychiatry
Steven L. Bernstein, MD, Emergency Medicine
Anne C. Black, PhD, Medicine (General Internal Medicine)
Ryan JJ Buckley, MD, MPH, Emergency Medicine
Susan Busch, PhD, Health Policy and Management
Dana Cavallo, PhD, Psychiatry
Magdalena Cerdá, DrPh, Chronic Disease Epidemiology
Marek Chawarski, PhD, Psychiatry and Emergency Medicine
Christopher Cutter, PhD, Psychiatry
Joao P. De Aquino, MD, Psychiatry
Ellen Lockard Edens, MD, MPE, Psychiatry
Sara Edmond, PhD, Medicine (General Internal Medicine)
John Encandela, PhD, Psychiatry
Claudia-Santi F. Fernandes, EdD, LPC, CHES, Medicine (General Internal Medicine)
David Fink, PhD, Medicine (General Internal Medicine)
Ariadna Forray, MD, Psychiatry
Abigail Friedman, PhD, Health Policy and Management
Lisa Fucito, PhD, Psychiatry
Stephanie Gillson, MD, Medicine (General Internal Medicine)
Abbe Gluck, JD, Law
Gregg Gonsalves, PhD, Epidemiology (Microbial Diseases)
Lauretta Grau, PhD, Epidemiology (Microbial Diseases)
Robert Heimer, PhD, Epidemiology (Microbial Diseases) and Pharmacology
Gretchen Hermes, MD, PhD, Psychiatry
Maria Christina Herrera, MD, MSHP, Pediatrics
Ayana Jordan, MD, PhD, Psychiatry
Amy Justice, MD, PhD, Medicine (General Internal Medicine)
Jennifer Kapo, MD, Medicine (Geriatric Medicine)
Robert Kerns, PhD, Psychiatry
Trace Kershaw, PhD, Public Health
Kaveh Khoshnood, PhD, MPH, Epidemiology (Microbial Diseases)
Brian Kiluk, PhD, Psychiatry
Michael Lyons, MD, MPH, Emergency Medicine
Lynn Madden, PhD, MPA, Medicine (Infectious Diseases)
John McDonagh, MD, Medicine (General Internal Medicine)
Sherry McKee, PhD, Psychiatry
Ted Melnick, MD, MHS, Emergency Medicine and Biostatistics
Brent Moore, PhD, Psychiatry
Srinivas Muvvala, MD, MPH, Psychiatry
Stephanie O'Malley, PhD, Psychiatry
Ijeoma Opara, PhD, LMSW, MPH, Social and Behavioral Sciences
Manuel Paris, PsyD, Psychiatry
Ismene Petrakis, MD, Psychiatry

Affiliated Faculty Cont.

Marc Potenza, MD, PhD, Psychiatry and Neuroscience
Yusuf Ransome, MPH, DrPH, Social and Behavioral Sciences
Elizabeth Roessler, MMSc, PA-C, Medicine (General Internal Medicine)
Yulia Rozanova, PhD, Medicine (Infectious Diseases)
Sheela Sheno, MD, MPH, FIDSA, Medicine (Infectious Diseases)
Julia Shi, MD, FACP, Medicine (General Internal Medicine)
Jody L. Sindelar, PhD, Public Health
Rajita Sinha, PhD, Psychiatry and Neuroscience
Adati Tarfa, PharmD, MS, PhD, Medicine (General Internal Medicine)
Daniel Tobin, MD, FACP, Medicine (General Internal Medicine)
Vasilis Vasiliou, PhD, Public Health
David Vlahov, DNP, Nursing and Epidemiology (Microbial Diseases)
Emily Wang, MD, MAS, Medicine (General Internal Medicine) and Social and Behavioral Sciences
Henry Yaggi, MD, MPH, Medicine (Pulmonary, Critical Care, and Sleep Medicine)

Program Staff

Operational

Emma Biegacki, MPH, Program Manager
Toni Boulay, Project Coordinator
Carolyn Dellaquila, Senior Administrative Assistant
Chelsey Gutierrez, MS, Project Manager
Rebecca Minahan-Rowley, LMSW, Project Manager

Clinical Research

Jessica McKenzie, MA, Research Associate III
Raiza Rossi, PhD, Post-Doctoral Associate
June-Marie Weiss, MA, MEd, Senior Project Manager

Yale Addiction Medicine Consult Service

Tracy Bachinski, LPN
Maisy Crews, MMSc, PA-C
Stephen Diaz, LMSW
Jared Franzman, MMSc, PA-C
Shayne McCarty
John O'Neil, LCSW
Lauryn Tetreault, MMSc, PA-C

Support Our Work

The Yale Program in Addiction Medicine is enhanced by the generous support of our donors. A gift of any amount can meaningfully advance our mission and goals, and make an impact on the work we do to improve care and outcomes for people impacted by substance use and addiction.

Ways to Give

Direct Donation

Donations in any amount are accepted online via [Yale University's institutional giving portal](#). Donors will be asked to complete a short form indicating the gift amount, type, contact information, and payment method.

Mailed Check

Checks should be made payable to the Yale University with Yale Program in Addiction Medicine indicated in the check memo.

Via US MAIL

Yale School of Medicine
Attn: Aliza Elwell
P.O. Box 7611
New Haven, CT 06519-0611

Via FED-EX or UPS

Office of Development
Yale School of Medicine
Attn: Aliza Elwell
157 Church Street
New Haven, CT 06510

Philanthropic Partnership

If you are interested in supporting our work and helping to advance meaningful impact in addiction medicine, we would welcome the opportunity to connect. Contributions of all kinds help strengthen our programs, expand access to care, support research and education, and advance innovative approaches to addressing substance use and addiction.

To learn more about ways to support our work, please contact Aliza Elwell at aliza.elwell@yale.edu or 203-432-2206.



Scan for more information on Giving to the Yale Program in Addiction Medicine.

Yale School of Medicine Office of Development



157 Church Street,
New Haven, CT 06510



203-432-2206



aliza.elwell@yale.edu



[medicine.yale.edu/
about/giving/](https://medicine.yale.edu/about/giving/)

